{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Texas+Retina+Associates",
    "query": {
      "sponsor": "Texas Retina Associates"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T17:38:27.164Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00527475",
      "title": "Ranibizumab and Reduced Fluence PDT for AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "verteporfin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Texas Retina Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2007-05",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2025-11-28",
      "last_synced_at": "2026-10-01T17:38:27.164Z",
      "location_count": 3,
      "location_summary": "Santa Barbara, California • Ann Arbor, Michigan • Arlington, Texas",
      "locations": [
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Arlington",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00527475"
    },
    {
      "nct_id": "NCT05486468",
      "title": "The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Uveitis",
        "Uveitis, Posterior",
        "Uveitis, Anterior",
        "Uveitis, Intermediate"
      ],
      "interventions": [
        {
          "name": "Yutiq 0.18 MG Drug Implant",
          "type": "DRUG"
        },
        {
          "name": "Sham Injection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Texas Retina Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2022-10-05",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-08-11",
      "last_synced_at": "2026-10-01T17:38:27.164Z",
      "location_count": 1,
      "location_summary": "Plano, Texas",
      "locations": [
        {
          "city": "Plano",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05486468"
    },
    {
      "nct_id": "NCT01295112",
      "title": "Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Non-Ischemic Central Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Active bevacizumab and Sham dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Active bevacizumab and Active dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Texas Retina Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2011-05",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2025-09-25",
      "last_synced_at": "2026-10-01T17:38:27.164Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01295112"
    },
    {
      "nct_id": "NCT03984110",
      "title": "One Year Trial Evaluating Safety of Ozurdex With Eylea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Ozurdex",
          "type": "DRUG"
        },
        {
          "name": "Eylea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Texas Retina Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2019-06-11",
      "completion_date": "2022-10-27",
      "has_results": false,
      "last_update_posted_date": "2024-04-10",
      "last_synced_at": "2026-10-01T17:38:27.164Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03984110"
    },
    {
      "nct_id": "NCT01728883",
      "title": "Diabetic Retinopathy And the Myvisiontrack® (DRAMA) Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetic Retinopathy",
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Home vision monitoring using myVisionTrack®",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Vital Art and Science Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2013-04",
      "completion_date": "2017-03",
      "has_results": false,
      "last_update_posted_date": "2017-05-12",
      "last_synced_at": "2026-10-01T17:38:27.164Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01728883"
    },
    {
      "nct_id": "NCT03816397",
      "title": "Adalimumab in JIA-associated Uveitis Stopping Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Uveitis",
        "JIA"
      ],
      "interventions": [
        {
          "name": "Adalimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Nisha Acharya",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2020-03-15",
      "completion_date": "2025-04-03",
      "has_results": true,
      "last_update_posted_date": "2025-05-11",
      "last_synced_at": "2026-10-01T17:38:27.164Z",
      "location_count": 11,
      "location_summary": "Sacramento, California • San Francisco, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03816397"
    },
    {
      "nct_id": "NCT00570479",
      "title": "Prophylactic Anecortave Acetate in Patients With a Retisert Implant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Uveitis, Posterior",
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "anecortave acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Texas Retina Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "10 Years to 80 Years"
      },
      "enrollment_count": 12,
      "start_date": "2006-09",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2012-06-05",
      "last_synced_at": "2026-10-01T17:38:27.164Z",
      "location_count": 1,
      "location_summary": "Arlington, Texas",
      "locations": [
        {
          "city": "Arlington",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00570479"
    }
  ]
}